A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients with Surgically Resectable Adenocarcinoma of the Pancreas
Demographics (2)
- COLLECTION_AGE - Age at time of surgery (phv00525499.v2.p1)
- SEX - Biological Sex (phv00525494.v2.p1)
Disease Events (2)
- AFFECTION_STATUS - Case control status of the subject for adenocarcinoma (phv00525498.v2.p1)
- OS - Overall Survival (phv00525506.v2.p1)
Other (21)
- ANALYTE_TYPE - Analyte Type (phv00525513.v2.p1)
- BATCH - Single-cell RNA-seq batch (1 or 2) (phv00542432.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00525512.v2.p1)
- CD4_Th17_Status - IHC Stain results indicating CD4+ and TH17 High/Low Status (Stain: CD3+CD4+RORgammaT+) (phv00525511.v2.p1)
- CD66b_Gr_Status - IHC Stain Indicating CD66b+ Granulocytes (Stain: CD3-CD66b+) (phv00525505.v2.p1)
- CD8_CD137_Status - IHC Stain results indicating CD8+ and CD137 High/Low status (Stain: CD3+CD8+CD137+) (phv00525508.v2.p1)
- Cell_Type - Sorted Cell Population (phv00525503.v2.p1)
- CONSENT - Consent group as determined by DAC (phv00525493.v2.p1)
- GEO_ACCESSION - GEO accession ID (GSM#) (phv00525501.v2.p1)
- IS_TUMOR - Tumor Status (phv00525514.v2.p1)
- M1_Status - IHC Stain results indicating High/Low M1 status (Stain: CD45+CSF1R+CD68+CD163-) (phv00525509.v2.p1)
- M2_Status - IHC Stain results indicating High/Low M2 status (Stain: CD45+CSF1R+CD68+CD163+) (phv00525510.v2.p1)
- RESPONSE - Pathological response (phv00555511.v1.p1)
- SAMPLE_ID - Sample ID (phv00525502.v2.p1)
- SAMPLE_ID - Sample ID (phv00525496.v2.p1)
- SAMPLE_ID - Sample ID (phv00525500.v2.p1)
- SUBJECT_ID - Subject ID (phv00525497.v2.p1)
- SUBJECT_ID - Subject ID (phv00525492.v2.p1)
- SUBJECT_ID - Subject ID (phv00525495.v2.p1)
- Treatment - Treatment Received (phv00525504.v2.p1)
- Treg_Status - IHC Stain results indicating High/Low Treg status (Stain: CD45+CD4+RORgammaT+) (phv00525507.v2.p1)